Fingerprint
Dive into the research topics of 'MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer
Valesca Pavlawna Retèl, Laura J. van ‘t Veer, F. Cardoso, M.J. Piccart, Emiel J.Th. Rutgers, K. Tryfonidis, C. Poncet, Willem H. van Harten
Research output: Contribution to journal › Meeting Abstract › Academic